| Literature DB >> 30389349 |
Irene Trinh1, Oxana B Gluscencova2, Gabrielle L Boulianne3.
Abstract
OBJECTIVE: Obesity is a complex disorder involving many genetic and environmental factors that are required to maintain energy homeostasis. While studies in human populations have led to significant progress in the generation of an obesity gene map and broadened our understanding of the genetic basis of common obesity, there is still a large portion of heritability and etiology that remains unknown. Here, we have used the genetically tractable fruit fly, Drosophila melanogaster, to identify genes/pathways that function in the nervous system to regulate energy balance.Entities:
Keywords: CNS; Diacylglycerol kinase; Drosophila; Insulin secretion; Metabolism; Obesity
Mesh:
Substances:
Year: 2018 PMID: 30389349 PMCID: PMC6323187 DOI: 10.1016/j.molmet.2018.10.006
Source DB: PubMed Journal: Mol Metab ISSN: 2212-8778 Impact factor: 7.422
Figure 1RNAi screening procedure and results. (A) TAG levels of all 1748 genes tested in the first round of RNAi screen. Data is normalized to a fru-Gal4/+ control. (B) Flowchart of RNAi screening procedure. 1748 genes were tested for a statistically significant change in triglyceride levels compared to control. Hits resulting in >25% ΔTAG or with homologues identified from GWAS underwent a second round of screening. Verified hits were then screened a third time using independent RNAi lines. 24 genes were confirmed by at least one independent RNAi line. (C) Enriched functional annotations among 24 final screen hits. GOTERM_BP, gene ontology: biological process; GOTERM_MF, gene ontology: molecular function.
Screen hits with human homologues that came out of genome-wide association studies for obesity-related traits.
| Gene | Human homologue(s) | GWAS phenotype | Reference(s) |
|---|---|---|---|
| Metabolic syndrome, fasting plasma glucose | |||
| Waist-hip ratio, Type 1 diabetes | |||
| Body mass index, weight, fasting glucose-related traits | |||
| Metabolic syndrome, Type 2 diabetes | |||
| Body mass index | |||
| Hypertriglyceridemia, Triglycerides | |||
| Body mass index, obesity, overweight | |||
| Triglycerides |
Figure 2Dgk knockdown or overexpression using fru-Gal4 alters lipid and carbohydrate homeostasis. (A) Knockdown of Dgk using two independent RNAi lines results in increased TAG. All bars are statistically significant by one-way ANOVA. (B) fru > Dgk RNAi flies have elevated glucose, glycogen but not trehalose levels. (C) Overexpression of either wild-type or kinase-dead Dgk results in lower TAG levels but does not alter trehalose levels. Kinase-dead Dgk but not wild-type Dgk also decreases glucose and glycogen levels. (A–C) Data is represented as percent of a fru-Gal4/+ control ± SD, n = 5. (D–E) Knockdown or overexpression of wild-type Dgk does not affect food intake. Flies overexpressing kinase-dead Dgk are hyperphagic. Data are represented as volume consumed by 3 flies over a 24h period ±SD, n = 30. All assays were performed three times but results from only one representative assay are shown. Asterisks denote p-values based on Student's t-test: *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 3Dgk regulates dILP secretion and insulin signaling pathway activity. (A) Knockdown of Dgk using dIlp2-Gal4 shows elevated TAG, glucose, and glycogen phenotypes. (B) dIlp2-Gal4-driven overexpression of kinase-dead Dgk but not wild-type Dgk also decreases glucose and glycogen levels. These phenotypes in (A–B) are similar to those seen using fru-Gal4. (C) fru > Dgk RNAi increases dILP2 and dILP5 levels in the hemolymph. (D) Overexpression of either Dgk.V5 or DgkG509D.V5 using fru-Gal4 does not affect hemolymph dILP2 or dILP5 levels. (A–D) Data is represented as percent or fold-change relative to a Gal4/+ control ± SD, n = 5. Assays were performed three times but results from only one representative assay are shown. (E–F) Knockdown or overexpression of Dgk with fru-Gal4 doesn't affect dIlp2 or dIlp5 transcript levels. Overexpression of DgkG509D.V5 increases dIlp3 levels. (G) fru-Gal4-driven Dgk RNAi or overexpression of DgkG509D.V5 result in lowered insulin pathway activity as measured by p-Ser505 Akt/total Akt levels. fru > Dgk.V5 did not affect pAkt/Akt levels. Quantification is from 3 biological replicates and is normalized to a fru-Gal4/+ control ±SD. Asterisks denote p-values based on student's t-test: *p < 0.05, **p < 0.01, ***p < 0.001.